Brant Point Investment Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Brant Point Investment Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-500	Closed	-$4.74M	–	134
2024 Q1	$4.74M	Buy	+500	New	+$46.4K	0.39%	51

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Brant Point Investment Management's XBI Position: Q1 2026 in Review

Brant Point Investment Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 18% in Q1 2026, selling an estimated $921K and leaving 33,866 shares worth $4.33M. The position accounts for 0.56% of the portfolio, ranked #47.

Brant Point Investment Management first reported a position in XBI in Q2 2020 and has held it in 24 quarters since. The position peaked at $6.75M in Q4 2021. 815 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Brant Point Investment Management held 33,866 shares of State Street SPDR S&P Biotech ETF worth $4.33M as of Q1 2026.
Brant Point Investment Management sold 7,376 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $921K.
State Street SPDR S&P Biotech ETF made up 0.56% of Brant Point Investment Management's portfolio in Q1 2026, its #47 holding.
Brant Point Investment Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and has held it in 24 quarters since.
Brant Point Investment Management's State Street SPDR S&P Biotech ETF position peaked at $6.75M in Q4 2021.
815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Brant Point Investment Management's 13F filing for Q1 2026, filed 14 May 2026.